Bio

Bio


Dr. Chaichian specializes in the diagnosis and management of all rheumatic diseases. As Director of the Stanford Lupus Clinic, he has a particular clinical and research interest in systemic lupus erythematosus (SLE). He has a secondary interest in connective tissue disease-associated interstitial lung disease. He is involved in a translational SLE research study at Stanford that seeks to identify novel means of risk-stratifying patients through the use of immune profiling. Under the guide of Dr. Mark Genovese, and in collaboration with Dr. Matthew Baker, he will be helping direct several upcoming clinical trials in SLE. He works closely with Dr. Julia Simard on epidemiologic research in lupus, including an interest in pregnancy outcomes in this patient population. Lastly, with Dr. Maurice Druzin of the Division of Maternal-Fetal Medicine, he has co-developed a multidisciplinary conference that focuses on the diagnostic and treatment approach to pregnancy in women with underlying connective tissue diseases.

Clinical Focus


  • Rheumatology
  • Systemic Lupus Erythematosus

Academic Appointments


Professional Education


  • Fellowship:University of Chicago Medical Center (2015) United States of America
  • Board Certification: Rheumatology, American Board of Internal Medicine (2014)
  • Residency:William S. Middleton Memorial Veterans Hospital (2012) WIUnited States of America
  • Board Certification: Internal Medicine, American Board of Internal Medicine (2011)
  • Residency:University of Wisconsin Hospital and Clinics (2011) WIUnited States of America
  • Internship:University of Wisconsin Hospital and Clinics (2009) WIUnited States of America
  • Medical Education:University of Iowa Carver College of Medicine (2008) IA

Research & Scholarship

Current Research and Scholarly Interests


Systemic lupus erythematosus
CTD-associated interstitial lung disease

Publications

All Publications


  • Do Death Certificates Underestimate the Burden of Rare Diseases? The Example of Systemic Lupus Erythematosus Mortality, Sweden, 2001-2013. Public health reports (Washington, D.C. : 1974) Falasinnu, T., Rossides, M., Chaichian, Y., Simard, J. F. 2018: 33354918777253

    Abstract

    OBJECTIVES: Mortality due to rare diseases, which are substantial sources of premature mortality, is underreported in mortality studies. The objective of this study was to determine the completeness of reporting systemic lupus erythematosus (SLE) as a cause of death.METHODS: In 2017, we linked data on a Swedish population-based cohort (the Swedish Lupus Linkage, 2001-2013) comprising people with SLE (n = 8560) and their matched general population comparators (n = 37717) to data from the Cause of Death Register. We reviewed death records of deceased people from the cohort (n = 5110) and extracted data on patient demographic characteristics and causes of death. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) for not reporting SLE as a cause of death by using multivariable-adjusted logistic regression models.RESULTS: Of 1802 deaths among SLE patients in the study, 1071 (59%) did not have SLE reported on their death records. Most SLE decedents were aged 75-84 at death (n = 584, 32%), female (n = 1462, 81%), and born in Nordic countries (n = 1730, 96%). Decedents aged ≥85 at death were more likely to have SLE not reported on their death records than were decedents aged <50 (OR = 2.34; 95% CI, 1.48-3.68). Having renal failure listed as a cause of death decreased the likelihood of SLE not being reported on the death record (OR = 0.54; 95% CI, 0.40-0.73), whereas having cancer listed as a cause of death increased this likelihood (OR = 2.39; 95% CI, 1.85-3.07).CONCLUSIONS: SLE was greatly underreported as a cause of mortality on death records of SLE patients, particularly in older decedents and those with cancer, thereby underestimating the true burden of this disease. Public health resources need to focus on improving the recording of rare diseases in order to enhance the epidemiological utility of mortality data.

    View details for DOI 10.1177/0033354918777253

    View details for PubMedID 29928843

  • The Representation of Gender and Race/Ethnic Groups in Randomized Clinical Trials of Individuals with Systemic Lupus Erythematosus. Current rheumatology reports Falasinnu, T., Chaichian, Y., Bass, M. B., Simard, J. F. 2018; 20 (4): 20

    Abstract

    This review evaluated gender and race/ethnic representation in randomized controlled trials (RCTs) of patients with systemic lupus erythematosus (SLE).Whites comprise 33% of prevalent SLE cases and comprised 51% of RCT enrollees. Blacks encompass 43% of prevalent SLE cases, but only represented 14% of RCT enrollees. Hispanics comprise 16% of prevalent SLE cases and 21% of RCT enrollees, while Asians comprise 13% of prevalent SLE cases and 10% of RCT enrollees. Males encompass 9% of SLE cases and 7% of RCT enrollees. The reporting and representation of males have remained stable over time, although their representation in RCTs is slighter lower than the prevalence of SLE in males. The representation of Hispanics, Asians, and Native Americans increased over time. However, the representation of blacks among RCT participants has decreased since 2006-2011. RCTs among SLE patients need larger sample sizes in order to evaluate heterogeneity in outcomes among racial subgroups. It is imperative that novel strategies be developed to recruit racial minorities with SLE by identifying and improving barriers to RCT enrollment in order to better understand the disease's diverse population.

    View details for DOI 10.1007/s11926-018-0728-2

    View details for PubMedID 29550947

  • Unraveling Race and Social Context in Understanding Disparities in Lupus Mortality in the United States Falasinnu, T., Chaichian, Y., Palaniappan, L., Simard, J. F. WILEY. 2017
  • Preterm Delivery Phenotypes in SLE Pregnancies Simard, J. F., Chaichian, Y., Rossides, M., Wikstrom, A., Shaw, G. M., Druzin, M. WILEY. 2017
  • Preterm Birth Phenotypes in Women with Autoimmune Diseases Kolstad, K. D., Mayo, J. A., Chung, L., Chaichian, Y., Kelly, V. M., Druzin, M., Stevenson, D. K., Shaw, G. M., Simard, J. F. WILEY. 2017
  • Impact of Sex on Systemic Lupus Erythematosus-Related Causes of Premature Mortality in the United States. Journal of women's health (2002) Falasinnu, T., Chaichian, Y., Simard, J. F. 2017

    Abstract

    Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is a source of significantly decreased life expectancy in the United States. This study investigated causes of deaths among males and females with SLE.This cross-sectional study used the national death certificate database of ∼2.7 million death records in the United States, 2014. SLE was defined using Tenth Revision of the International Classification of Diseases codes: M32.1, M32.9, and M32.8. We compared sex-stratified demographic characteristics and the most commonly listed comorbidities in decedents with and without SLE. Relative risks (RRs) quantified the risk of dying with the most commonly listed comorbidities among decedents with SLE aged ≤50 years compared with non-SLE decedents.There were 2,036 decedents with SLE in the United States (86.2% female). Female SLE decedents were 22 years younger than non-SLE females (median: 59 years vs. 81 years). This difference was 12 years among male decedents (median: 61 years vs. 73 years). The most frequently listed causes of death among female SLE decedents were septicemia (4.32%) and hypertension (3.04%). In contrast, heart disease (3.70%) and diabetes mellitus with complications (3.61%) were the most common among male SLE decedents. Among younger male decedents, SLE had higher co-occurrence of coagulation/hemorrhagic disorders and chronic renal failure compared with non-SLE (RR = 16.69 [95% confidence interval {CI} = 10.50-27.44] and RR = 5.76 [95% CI = 2.76-12.00], respectively). These also contributed to premature mortality among women (RR = 4.98 [95% CI = 3.69-6.70] and 8.55 [95% CI = 6.89-10.61], respectively).Our findings identify clinically relevant comorbidities that may warrant careful consideration in patients' clinical management and the natural history of SLE.

    View details for DOI 10.1089/jwh.2017.6334

    View details for PubMedID 28891746

  • Long-term Management of Gout: Nonpharmacologic and Pharmacologic Therapies Rheumatic Disease Clinics of North America Chaichian, Y., Chohan, S., Becker, M. A. 2014; 40 (2)
  • Targeted Therapies in Systemic Lupus Erythematosus: A State-of-the-Art Review Journal of Clinical & Cellular Immunology Chaichian, Y., Utset, T. O. 2013; 4 (S6)